Summary & Overview
HCPCS S3800: Genetic Testing for Amyotrophic Lateral Sclerosis
HCPCS Level II code S3800 designates genetic testing for amyotrophic lateral sclerosis (ALS), a specialized laboratory diagnostic service that informs diagnosis, family counseling, and potential clinical trial eligibility. Nationally, genetic testing for ALS is increasingly important as precision medicine and gene-targeted therapies evolve; the code captures a distinct, billable service used across outpatient and laboratory settings. Key payers in the review include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for ALS genetic testing, how major payers approach coverage and coding for specialized genetic services, and benchmarking material where available. The publication outlines reimbursement patterns, common billing modifiers, and operational considerations for submitting claims for S3800. It also summarizes policy and coverage trends that affect access to genetic testing, and highlights documentation and service-line implications for laboratories and clinicians. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code S3800 represents genetic testing for amyotrophic lateral sclerosis (ALS). The service is a laboratory-based genetic diagnostic test intended to identify genetic variants associated with ALS.
- Typical site of service: clinical laboratory or outpatient diagnostic laboratory
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 48-year-old patient with progressive asymmetric limb weakness, fasciculations, and dysarthria is referred to a neuromuscular clinic for evaluation of suspected amyotrophic lateral sclerosis (ALS). The neurologist documents a detailed history, neurologic exam, and electromyography that support a motor neuron disease process. Genetic counseling is provided and written informed consent is obtained for targeted and panel genetic testing to assess for pathogenic variants associated with familial and sporadic ALS. A peripheral blood sample is collected in the clinic or an outpatient laboratory and sent to a certified molecular diagnostic laboratory for analysis under billing code S3800 (Genetic testing for amyotrophic lateral sclerosis).
The typical workflow includes: pre-test genetic counseling, specimen collection and labeling, shipping to the reference laboratory, laboratory testing (single-gene sequencing and/or multigene panel including common ALS genes such as C9orf72, SOD1, TARDBP, FUS), reporting of results with interpretation, and post-test counseling to discuss pathogenic, likely pathogenic, variant of uncertain significance, or negative results. Results may impact family counseling, cascade testing of relatives, clinical prognosis, and eligibility for gene-targeted clinical trials. The typical site of service is an outpatient neurology clinic or an ambulatory phlebotomy/laboratory collection center. Frequently involved providers include neurologists, genetic counselors, and clinical laboratory specialists.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|